The pharmaceutical industry continues to be a hotbed of patent innovation. Activity is driven by the evolution of new treatment paradigms, and the gravity of unmet needs, as well as the growing importance of technologies such as pharmacogenomics, digital therapeutics, and artificial intelligence. In the last three years alone, there have been over 787,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Genomics in pharma: CRISPR vectorsBuy the report here.

Smarter leaders trust GlobalData

Report-cover

Premium Insights Innovation in Pharmaceuticals: CRISPR vectors

Buy the Report

Premium Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s Technology Foresights, which uses over 668,000 patents to analyze innovation intensity for the pharmaceutical industry, there are 80+ innovation areas that will shape the future of the industry.

CRISPR vectors is a key innovation area in genomics

CRISPR/Cas9 gene editing system works by cutting DNA precisely and allowing natural DNA repair processes to take over. The system consists of two parts, the Cas9 enzyme and a guide RNA. The delivery of CRISPR/Cas9 components into the cell fall into two broad categories, viral and non-viral.

GlobalData’s analysis also uncovers the companies at the forefront of each innovation area and assesses the potential reach and impact of their patenting activity across different applications and geographies. According to GlobalData, there are 240+ companies, spanning technology vendors, established pharmaceutical companies, and up-and-coming start-ups engaged in the development and application of CRISPR vectors.

Key players in CRISPR vectors – a disruptive innovation in the pharmaceutical industry



‘Application diversity’ measures the number of applications identified for each patent. It broadly splits companies into either ‘niche’ or ‘diversified’ innovators.

‘Geographic reach’ refers to the number of countries each patent is registered in. It reflects the breadth of geographic application intended, ranging from ‘global’ to ‘local’.


Patent volumes related to CRISPR vectors

Company Total patents (2010 - 2022) Premium intelligence on the world's largest companies
CRISPR Therapeutics 279 Unlock Company Profile
Editas Medicine 238 Unlock Company Profile
Inscripta 219 Unlock Company Profile
E. Merck 207 Unlock Company Profile
Massachusetts General Hospital 140 Unlock Company Profile
Regeneron Pharmaceuticals 124 Unlock Company Profile
Intellia Therapeutics 118 Unlock Company Profile
Beam Therapeutics 105 Unlock Company Profile
Caribou Biosciences 88 Unlock Company Profile
Vertex Pharmaceuticals 87 Unlock Company Profile
Bayer 74 Unlock Company Profile
General Hospital 74 Unlock Company Profile
ToolGen 68 Unlock Company Profile
Arbor Biotechnologies 67 Unlock Company Profile
Sangamo Therapeutics 65 Unlock Company Profile
Bristol-Myers Squibb 63 Unlock Company Profile
Fate Therapeutics 52 Unlock Company Profile
KSQ Therapeutics 51 Unlock Company Profile
Modalis Therapeutics 50 Unlock Company Profile
Jackson ImmunoResearch Laboratories 48 Unlock Company Profile
Seattle Children's Hospital 46 Unlock Company Profile
CIBUS US 44 Unlock Company Profile
Cibus Europe 42 Unlock Company Profile
Danaher 41 Unlock Company Profile
EdiGene 39 Unlock Company Profile
Cellectis 39 Unlock Company Profile
IONTAS 36 Unlock Company Profile
Corteva 36 Unlock Company Profile
Verneuil Participations 34 Unlock Company Profile
Flagship Pioneering 34 Unlock Company Profile
AnGes 34 Unlock Company Profile
G+FLAS Life Sciences 33 Unlock Company Profile
Tropic Biosciences UK 31 Unlock Company Profile
Puretech Health 31 Unlock Company Profile
Intima Bioscience 31 Unlock Company Profile
Keygene 30 Unlock Company Profile
Verve Therapeutics 30 Unlock Company Profile
Fred Hutchinson Cancer Research Center 29 Unlock Company Profile
Application of Information and Communication Technologies (AICT) 28 Unlock Company Profile
Excision BioTherapeutics 28 Unlock Company Profile
Children's Hospital of Philadelphia 27 Unlock Company Profile
Sanofi 26 Unlock Company Profile
Arc Bio 25 Unlock Company Profile
ElevateBio 24 Unlock Company Profile
Royal DSM 23 Unlock Company Profile
SNIPR Biome 21 Unlock Company Profile
Ginkgo Bioworks 21 Unlock Company Profile
Rocket Pharmaceuticals 21 Unlock Company Profile
Illumina 20 Unlock Company Profile
Astellas Pharma 20 Unlock Company Profile

Source: GlobalData Patent Analytics

CRISPR Therapeutics is the leading patent filer in CRISPR vectors. It is a gene editing company and focuses on the development of transformative medicines using its proprietary CRISPR/Cas9 gene-editing platform. Its major development programs include ex vivo programs involving gene editing of hematopoietic cells, ex vivo programs in immuno-oncology, in vivo programs targeting the liver, and additional in vivo programs targeting other organ systems, including muscle and lung.

In terms of application diversity, Puretech Health is the top company, followed by Sanofi and IONTAS. By means of geographic reach, Cibus US holds the top position. Cibus Europe and IONTAS stand in second and third positions, respectively.

To further understand the key themes and technologies disrupting the pharmaceutical industry, access GlobalData’s latest thematic research report on Genomics.

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Patent Analytics tracks patent filings and grants from official offices around the world. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the world’s largest industries.